Erich Platzer

Nitinotes is a privately-held medical device company based in Caesarea, Israel that focuses on providing a safer and simpler suturing solution for endoscopic gastroplasty. Its flagship product, the EndoZip™, is an endoscopic robotic suturing system that has been backed by clinical success and prominent KOLs. By simplifying and speeding up the suturing process, EndoZip™ makes endoscopic gastroplasty a widely available, easy-to-perform procedure that offers an effective and minimally-invasive solution for more than 700 million patients with obesity class I & II for whom traditional bariatric surgery is not an option.

Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer. With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.

MTIP is a leading Swiss-based growth equity firm investing in European healthtech companies that aim to revolutionize global healthcare. We leverage our deep sector expertise to help the founders scale up successful and sustainable digital health businesses.

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Nitinotes is a privately-held medical device company based in Caesarea, Israel that focuses on providing a safer and simpler suturing solution for endoscopic gastroplasty. Its flagship product, the EndoZip™, is an endoscopic robotic suturing system that has been backed by clinical success and prominent KOLs. By simplifying and speeding up the suturing process, EndoZip™ makes endoscopic gastroplasty a widely available, easy-to-perform procedure that offers an effective and minimally-invasive solution for more than 700 million patients with obesity class I & II for whom traditional bariatric surgery is not an option.

Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer. With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.

MTIP is a leading Swiss-based growth equity firm investing in European healthtech companies that aim to revolutionize global healthcare. We leverage our deep sector expertise to help the founders scale up successful and sustainable digital health businesses.

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).